title: TLR4 activates NF-κB in human ovarian granulosa tumor cells.
abstract: Previous studies have demonstrated expression of Toll-like receptors (TLRs) in the surface epithelium of normal ovaries (OSE) and in epithelial ovarian tumors. Most notably, OSE-derived cancers express TLR4, which activates the nuclear factor-kappa B (NF-κB) signaling cascade as a mediator of inflammatory response. Currently, there is considerable interest in elucidating the role of TLR-mediated signaling in cancers. Nevertheless, the expression of TLRs in granulosa cell tumors (GCTs) of the ovary, and the extent to which GCT expression of TLRs may influence cell-signaling pathways and/or modulate the efficacy of chemotherapeutics, has yet to be determined. In the present study, human GCT lines (COV434 and KGN) were utilized to evaluate expression of functional TLR4. TLR4 is expressed in GCT cell lines and ligation of TLR4 with bacterial lipopolysaccharide (LPS) led to IκB degradation and activation of NF-κB. NF-κB activation was confirmed by nuclear localization of NF-κB p65 following treatment with LPS and the naturally occurring ligand, HSP60. Notably, immunoneutralization of TLR4 blocked nuclear localization, and inhibition of NF-κB signaling attenuated LPS-induced TNFα plus increased doubling time in both cell lines. Contradictory to reports using human OSE cell lines, inhibition of NF-κB signaling failed to sensitize GCT lines to TRAIL or cisplatin. In summary, findings herein are the first to demonstrate a functional TLR-signaling pathway specifically in GCTs, and indicate that in contrast to OSE-derived cancers, inhibition of NF-κB does not sensitize GCTs to TRAIL or cisplatin.
authors: Vincent Center for Reproductive Biology, Vincent Obstetrics and Gynecology Service, Massachusetts General Hospital/Harvard Medical School, Boston, MA 02114, USA. dwoods2@partners.org
authors: Dori C
authors: DC
authors: Woods
authors: Yvonne A R
authors: YA
authors: White
authors: Caroline
authors: C
authors: Dau
authors: A L
authors: AL
authors: Johnson
references: Reproduction. 2009 Jun;137(6):987-96
references: 19336472
references: Clin Cancer Res. 2011 Apr 15;17(8):2181-94
references: 21339307
references: Endocrinology. 2001 Jan;142(1):437-45
references: 11145608
references: Mol Endocrinol. 2006 Dec;20(12):3228-39
references: 16931571
references: Cancer Immunol Immunother. 2009 Sep;58(9):1375-85
references: 19184006
references: Cancer Lett. 2006 Apr 8;235(1):75-83
references: 15922507
references: Hepatology. 2000 Sep;32(3):482-90
references: 10960439
references: Methods. 2001 Dec;25(4):402-8
references: 11846609
references: Oncogene. 2009 Dec 10;28(49):4353-63
references: 19826413
references: Oncogene. 2008 Jan 7;27(2):218-24
references: 18176603
references: Gynecol Oncol. 2008 Mar;108(3):632-40
references: 18191995
references: Scand J Immunol. 2000 Mar;51(3):244-50
references: 10736093
references: J Clin Oncol. 2003 Mar 15;21(6):1180-9
references: 12637488
references: Reproduction. 2007 Apr;133(4):733-41
references: 17504917
references: Anticancer Res. 2000 Nov-Dec;20(6B):4243-55
references: 11205254
references: Science. 1995 Mar 10;267(5203):1485-8
references: 7878466
references: Annu Rev Physiol. 2002;64:69-92
references: 11826264
references: FASEB J. 2004 Jul;18(10):1117-9
references: 15132988
references: Science. 1997 Aug 8;277(5327):818-21
references: 9242611
references: Cancer Res. 2006 Apr 1;66(7):3859-68
references: 16585214
references: Cancer Lett. 2003 May 8;194(1):107-17
references: 12706864
references: Blood. 1998 Jun 15;91(12):4624-31
references: 9616159
references: Mol Hum Reprod. 2000 Feb;6(2):146-53
references: 10655456
references: Cell. 2007 Jun 15;129(6):1065-79
references: 17574021
references: Cancer Lett. 2008 Feb 18;260(1-2):20-7
references: 18031928
references: Cancer Cell. 2004 Sep;6(3):297-305
references: 15380520
references: J Clin Oncol. 2007 Jul 10;25(20):2944-51
references: 17617526
references: Breast Cancer Res Treat. 2000 Nov;64(2):211-9
references: 11194457